Strong Revenue, Drug Performance Lift Catalyst Shares

CPRX is a biopharmaceutical company that develops and commercializes therapies for rare and challenging diseases. The company’s FirdApps (the only evidence-based treatment for Lambert-Eaton Myasthenic syndrome) and Agamri products have both gained significant traction over the last year. Also, a recent court win related to a patent keeps the FirdApps intellectual property intact until February 2035, when generics can enter the market.

Earnings-wise, CPRX’s fourth-quarter fiscal 2024 report showed record revenue growth of 23.5% for the year, up to $491.7 million. The company has more than $517 million on hand for future initiatives – and best of all, no debt. FirdApps grew 18.3% year-over-year and Agamri generated $46 million after launching in March 2024. Per-share earnings came in at $1.31 per diluted share on a GAAP basis. Going forward, CPRX expects up to $565 million in revenue this year.

It’s no wonder CPRX shares are up 23% this year – and they could rise more. MAPsignals data shows how Big Money investors are betting heavily on the forward picture of the stock.

Big Money Buying Catalyst

Institutional volumes reveal plenty. Recently, CPRX has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in CPRX shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Catalyst.

Catalyst Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, CPRX has had strong sales and earnings growth:

• 3-year sales growth rate (+53.8%)
• 3-year earnings growth rate (+66.7%)

Source: FactSet

Plus, EPS is estimated to ramp higher this year by +17.7%.

Now it makes sense why the stock has been powering to new heights. CPRX has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Catalyst has been a top-rated stock at MAPsignals for a few years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Top 20 report multiple times in the last three years. The blue bars below show when CPRX was a top pick…rising up with Big Money support:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Catalyst Price Prediction

The CPRX rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in CPRX at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MAPsignals process here.